Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ADH5 | P11766 | 6/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24419157 | 0.81 | KDR (0.43) | SCN5AESR1POLB | |
| SCHEMBL3081703 | 0.78 | ESR1 (0.47) | SCN5AESR1HTTKDM5AKDM4C | |
| SCHEMBL24419148 | 0.76 | NR4A2 (0.41) | NR4A2KEAP1ADH5KDM5AKDM4C | |
| SCHEMBL3972917 | 0.72 | NR4A2 (0.64) | NR4A2KEAP1 | |
| SCHEMBL4183564 | 0.72 | NR4A2 (0.58) | NR4A2KEAP1KDM5AKDM4CKDM5B | |
| SCHEMBL13212874 | 0.71 | SCN5A (0.59) | SCN5APIK3CD | |
| SCHEMBL27808338 | 0.71 | KDM4E (0.58) | NR4A2KEAP1KDM5AKDM4CKDM5B | |
| SCHEMBL363026 | 0.70 | KMO (0.59) | NR4A2HTT | |
| SCHEMBL24419177 | 0.70 | MAP4K4 (0.43) | NR4A2EGLN1 | |
| SCHEMBL24419353 | 0.70 | NR4A2 (0.38) | NR4A2HTTADH5KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931191-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | PDXK, PASK, NADK | NR4A2 1114/4885SCN5A 1122/4885ESR1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.